ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are standard therapy for chronic myelogenous leukemia (CML).
• Significant patient populations develop primary or acquired resistance to TKIs, necessitating alternative treatments.
• Leukemic clones escaping TKI therapy pose a challenge in CML management.

Purpose of the Study:

• To investigate the efficacy of a novel oligonucleotide, ASP210, against TKI-resistant CML cells.
• To assess ASP210's ability to reduce BCR-ABL1 mRNA levels and induce apoptosis in resistant CML.
• To evaluate the safety and selectivity of ASP210 in preclinical models.

Main Methods:

• Established imatinib- and dasatinib-resistant sublines of BCR-ABL1-positive MOLM-7 and CML-T1 cells.
• Treated resistant cells with ASP210 (0.25 and 2.5 µM) for 10 days.
• Quantified BCR-ABL1 mRNA levels using RT-qPCR and monitored cell viability via trypan blue staining.

Main Results:

• ASP210 significantly reduced BCR-ABL1 mRNA levels by over 99% after a single application.
• TKI-resistant CML cells underwent apoptosis by day 5 post-redosing, irrespective of the T315I mutation.
• ASP210 demonstrated selective toxicity towards cancer cells, indicating a favorable safety profile.

Conclusions:

• ASP210 is a potent oligonucleotide therapeutic candidate for TKI-resistant CML.
• Its ability to induce apoptosis in resistant cells, including those with the T315I mutation, offers a new treatment avenue.
• The drug's selective action and potential for low-dose efficacy warrant further clinical investigation.